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Abstract
The large diversity in MHC class I molecules in a population lowers the chance that a virus infects a host to which it is pre-
adapted to escape the MHC binding of CTL epitopes. However, viruses can also lose CTL epitopes by escaping the
monomorphic antigen processing components of the pathway (proteasome and TAP) that create the epitope precursors. If
viruses were to accumulate escape mutations affecting these monomorphic components, they would become pre-adapted
to all hosts regardless of the MHC polymorphism. To assess whether viruses exploit this apparent vulnerability, we study the
evolution of HIV-1 with bioinformatic tools that allow us to predict CTL epitopes, and quantify the frequency and
accumulation of antigen processing escapes. We found that within hosts, proteasome and TAP escape mutations occur
frequently. However, on the population level these escapes do not accumulate: the total number of predicted epitopes and
epitope precursors in HIV-1 clade B has remained relatively constant over the last 30 years. We argue that this lack of
adaptation can be explained by the combined effect of the MHC polymorphism and the high specificity of individual MHC
molecules. Because of these two properties, only a subset of the epitope precursors in a host are potential epitopes, and
that subset differs between hosts. We estimate that upon transmission of a virus to a new host 39%–66% of the mutations
that caused epitope precursor escapes are released from immune selection pressure.
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Introduction
Antigen presentation allows CD8
+ T cells to monitor the protein
content of a cell and detect the presence of intracellular viruses [1].
The classical antigen presentation pathway consists of three main
steps: the (immuno-)proteasome, which cleaves cytoplasmic
proteins into peptide fragments; the transporter associated with
antigen processing (TAP), which transports peptide fragments into
the endoplasmic reticulum; and the major histocompatibility
complex (MHC) class I, which binds a small fraction of these
endoplasmic peptide fragments [2], and transports them to the cell
surface [3–5]. The peptide fragments that are processed by the
proteasome and transported by TAP are commonly called ‘epitope
precursors’.
Of these three steps in the antigen presentation pathway it is
only the MHC that is highly polymorphic, which is thought to
have evolved because of the rare allele advantage [6–8]: hosts that
carry rare MHC alleles are less likely to be infected by viruses that
are adapted to escape the host’s MHC alleles than hosts with
common MHC alleles, because it is less likely that these viruses
come from a host with the same rare MHC alleles. Therefore hosts
with rare MHC alleles are thought to have a fitness advantage.
Indeed, hosts that were infected with preadapted variants of the
human immunodeficiency virus 1 (HIV-1) were found to progress
rapidly to AIDS [9–11]. However, if viruses adapt to escape the
epitope precursors [12–15], which are created by the monomor-
phic proteasome and TAP, the protective effect of the MHC
polymorphism and the fitness advantage of hosts with rare MHC
alleles would be lost.
We studied the ability of HIV to generate and accumulate epitope
and epitope precursor escapes, using algorithms that can reliably
predict the likelihood of proteasomal cleavage, TAP transport, and
MHC binding of amino acid sequences (see Material & Methods).
We discovered that there is no accumulation of epitope precursor
escapes on the population level: the total number of epitope
precursors (as well as that of epitopes) has remained relatively
constant over the last 30 years. We explored several possible causes
for this lack of adaptation to the antigen processing machinery, and
postulate a mechanismbywhich thespecificity and polymorphismof
the MHC prevents the adaptation of viruses to the monomorphic
parts of the antigen presentation pathway.
Materials and Methods
CTL epitope predictions
Currently, a wide variety of algorithms [16–19] are available to
predict MHC-peptide binding. The capacity of these algorithms to
identify new epitopes has routinely been tested on experimental
data [20,21], and their accuracy has increased over time to such
an extent that the correlation between predicted and measured
binding affinity is as good as the correlation between measure-
ments from different laboratories [20]. A further increase in
PLoS ONE | www.plosone.org 1 October 2008 | Volume 3 | Issue 10 | e3525accuracy of identifying Cytotoxic T lymphocytes (CTL) epitopes is
achieved by combining the MHC binding predictors with
predictors trained to mimic the specificity of the proteasome and
TAP, thus creating a model of the complete antigen presentation
pathway [19,22,23]. These pathway models come in two types:
those that sum the scores of the independent steps of the antigen
processing pathway, and use a threshold on the summed score (e.g.
MHC-pathway [23] and NetCTL [22]), and those that eliminate
epitope candidates at each step (e.g. EpiJen [19], MAPPP [24] and
the alternative implementation of MHC-pathway [23]).
In this study we use the alternative implementation of the
MHC-pathway model [23]. We screen all possible peptide
fragments of 14 amino acids within a particular protein, and
eliminate those fragments that cannot be correctly processed by
either the proteasome, TAP or the MHC class I molecules (Fig. 1).
This approach allows us to distinguish between adaptation of a
virus to antigen processing and adaptation to MHC class I
binding. The threshold values for the proteasome and TAP
predictors (Fig. 1) were derived by applying the MHC-pathway
model to a large bacterial protein data set and selecting threshold
values which correspond to the estimated specificity of the
proteasome (33%) and TAP (76%) [25]. For the MHC-binding
predictions we used the default threshold of 22.7, which
corresponds to an IC50 threshold of 500 nM [2,20]. As a result of
using500 nMasthethresholdforMHCbindingouranalysisfocuses
on the medium to strong HIV-1 epitopes, and disregards the weaker
CTL epitopes in the 500–5000 nM range in favor of a higher
specificity (i.e. less false positives) of the MHC-pathway model. The
dependency of our results on the selected thresholds and the selected
predictor was tested by repeating the population and ancestor
analysis for the HIV-1 clade B ENV, GAG and NEF proteins, using
a more relaxed MHC binding criteria (5000 nM), as well as using
another prediction algorithm, NetCTL [22]. The predictors used in
this paper are available through a web interface (http://tools.
immuneepitope.org/analyze/html/MHC_binding.html 2006-01-
01 version). Note that we excluded 2 of the 34 available MHC
predictors. The A*3002 predictor was very non-specific at our
thresholds, predicting MHC binding in as much as 9944 out of
50.000 HIV-1 derived 9mers (20%). The B*0801 MHC predictor
appeared to be very specific, and predicted no MHC binding in
50.000 HIV-1 derived 9mers at the thresholds we use.
Prediction quality
Epitope predictors are routinely tested on large sets of epitopes
derived from various pathogens [20,26]. More recently, Larsen et al.
[21] tested the performance of four widely used predictors on a data
set of only HIV-1 epitopes. In that study, NetCTL and MHC-
pathway came out as the best performing algorithms. MHC-
pathway is estimated to recover 80% of the known epitopes at a
specificity of 90%, and recover 30% of the known epitopes at a
specificity of 99.3%. However, Larsen et al. [21] stressed that these
specificity ratings were underestimates, as the test data set was build
withtheassumptionthatanypeptidethatisn’taknownCTLepitope
mustbe a non-epitope, duetothe lackof confirmed non-epitopes.As
a result, many of the correctly predicted but experimentally not yet
verified epitopes were scored as erroneous predictions. A second
issue that makes the exact estimation of prediction quality difficult is
that many of the experimentally confirmed epitopes are based on
CTL responses measured against overlapping peptide pools, and are
often defined as the best responding amino acid substring within a
peptide that elicits a T cellresponse, regardless of whether or not this
substring is a peptide that can be naturally processed. A more
reliable way to estimate the specificity of the predictors is to predict a
set of CTL epitopes and subsequently verify CD8
+ Tc e l lr e s p o n s e s
against these epitopes experimentally. Schellens et al. [27] identified
18 new CTL epitopes out of a set of 22 predicted CTL epitopes in
this manner (using NetCTL). This suggests that the specificity of the
predictors is far higher than the benchmark estimates, and places the
amount of false positive predictions at 20%. Pe ´rez et al [28]
identified 114 out of 184 predicted epitopes (38% false positives) in a
similar manner, but predicted CTL epitopes for the MHC
supertypes rather than genotypes, which may explain their higher
rateoffalsepositives.Amoredirectapproachtomeasuringpredictor
quality is the use of mild acid elution and mass spectrometry to
determine MHC-binding peptides. Using these techniques Fortier et
al. [29] estimated the false positive rate of the MHC-binding
predictors of the MHC-pathway model to be less than 2%.
HIV-1 longitudinal within-host data
In December 2007, we performed an exhaustive search on the
HIV Sequence Database (http://hiv.lanl.gov) for longitudinal
within-host sequences from 4 digit HLA-genotyped patients that
had not received antiretroviral therapy, and for which at least 3
matching MHC predictors were available. This resulted in a data
set of 13 patients for which GAG, NEF and POL protein
sequences were available (see Table S1 and S2 for sampling dates
and accession numbers). All patients were infected with HIV-1
clade B, and their sample HIV-1 sequences spanned a time period
of at least two years. The time between infection with HIV-1 and
extraction of the early sequence sample was in all cases less than a
year. Surprisingly, 8 out of 13 patients carried HLA-B5701 and/or
HLA-B2705, two rare and protective alleles [30,31], which
probably reflects an observation bias in the data base. All
longitudinal within-host sequences were translated from nucleotide
to protein sequences with the GeneCutter tool (http://www.hiv.
lanl.gov/content/sequence/HIV/HIVTools.html). For patient
PIC1362(1052829) multiple sequences per protein per timepoint
were available, with small differences between each sequence. Not
knowing which of the early timepoints (if any) was the ancestral
sequence of the late timepoints complicated some of the within-
host analysis. We took a prudent approach by excluding from the
analysis the amino acid positions and CTL epitopes for which
Figure 1. Schematic of the MHC-pathway model. A window of 14
amino acids is slided across a protein. Each of these ‘14mers’ consists of
a N-terminal flanking region of 1 amino acid, a 9mer epitope candidate
and a C-terminal flanking region of 4 amino acids. Beneath the 14mer
the parts of the peptide that are used by the MHC, TAP or proteasome
predictors are marked. Applying the 14mer to the MHC, TAP and
proteasome predictors results in three different scores. If each of these
scores is higher than a fixed threshold, then the 9mer embedded in the
14mer is predicted to be a CTL epitope for the MHC allele tested (in this
case A*0201). If a 14mer passes at least the proteasome and TAP
predictors then the 9mer embedded in the 14mer is predicted to be an
epitope precursor. In the analysis of longitudinal within-host data sets,
CTL epitopes are scored as escapes if mutations in the 14-mer lower
one of the three scores below the corresponding threshold.
doi:10.1371/journal.pone.0003525.g001
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a particular epitope was present in the majority of the early
timepoint sequences, but not in any of the late timepoint
sequences, there are two possibilities: the early timepoint
sequences that still contained the epitope escaped it, or the early
timepoint sequences that did not contain the epitope outcompeted
those sequences that did contain the epitope. In such cases the
epitope was excluded from the analysis.
HIV-1 population data
The HIV-1 population data set used in this paper is the HIV-1
clade B subset of the aligned HIV-1 Sequence Compendium 2002
(Dec 2007 version) [32]. This data set was pruned of sequences for
which the sampling date was unknown. The sequence compendium
consists of 9 aligned fasta files, one for each of HIV-1’s proteins. The
number of available HIV-1 clade B sequences in the compendium
differs per protein and ranges from 96 to 386 sequences (see Table
S3 for details). The correlations in Fig. 2 and Fig. 3 were determined
with the Kendall Tau rank correlation test [33] of the statistical
package R [34]. The predicted HIV-1 clade B ancestor sequence
[35] (available at http://www.hiv.lanl.gov/content/sequence/
NEWALIGN/align.html) was aligned to the population data set
with HMMER 2.3.2 [36], a profile hidden Markov model.
Results
Adaptation to the human population
To determine whether HIV has exploited the lack of
polymorphism of the proteasome and TAP, we predicted the
number of epitope precursors in a HIV-1 clade B sequence
population data set with samples from 1980 to 2005 (see Material
& Methods for details on the HIV-1 Sequence Compendium data
set [32] and the quality of the MHC-pathway model [21]). We
plotted the predicted epitope precursor density of each HIV-1
sequence against its sampling date to study the changes over time
(Fig. 2, first column & Table S3). Using 32 MHC peptide binding
predictors, the same procedure was followed to plot the average
density of MHC-binding peptides, and the average density of CTL
epitopes. In all three cases there was no sign of any large-scale
adaptation of HIV-1 clade B to its human host over the last 30
years: the number of epitope precursors, MHC-binding peptides
and CTL epitopes per HIV-1 sequence remained constant over
time. Differences existed mainly between proteins: the envelope
protein (ENV) seemed more immunogenic and had a higher
density of precursors, MHC-binders and CTL epitopes than the
other proteins, and the NEF protein showed a far greater
variability between sequences than the other proteins. In addition
to the proteins shown in Fig. 2, the same analysis was performed
for the other proteins of HIV-1 (Table S3), for two other HIV-1
clades (clade C (Table S4) and clade A1 (Table S5)), as well as for
human subpopulations (Kroatia, UK & USA (Table S6)) within
the HIV-1 clade B population data set. This resulted in a total of
102 tests, of which 14 were found to be significant at a p-value of
,0.01 (Kendall Tau rank correlation test). However, in 6 out of
these 14 significant cases HIV-1 was gaining epitope precursors,
MHC-binding peptides, or CTL epitopes over time. The 7 cases in
which the density significantly decreased over time were not
consistently occurring in the same proteins when comparing
different HIV-1 clades, nor were they consistently affecting the
same step in the antigen presentation pathway. This makes it
unlikely that these 7 correlations reflect the adaptation of HIV-1 to
its human host. We verified our results by repeating the analysis for
ENV, GAG and NEF using a more relaxed MHC binding threshold
(5000 nM), as well as with a different prediction algorithm [21] (data
not shown). This did not result ina qualitative difference, except that
according to the NetCTL predictions [21] the epitope precursor
Figure 2. The predicted density of epitope precursors, MHC-binding peptides and CTL epitopes in ENV, GAG and NEF stay constant
over time. The density (expressed as frequency per amino acid) is plotted on the y-axis with the same scale factor within each column, which makes
it possible to compare differences between proteins. The densities for MHC-binding and CTL epitopes are averaged over the 32 MHC-binding
predictors. *: significant increase over time (Kendall Tau rank correlation test, p,0.01).
doi:10.1371/journal.pone.0003525.g002
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(Kendall Tau rank correlation test, p,0.01. Epitope precursor
density is predicted to change from 49 precursors in 2008, to an
estimated 46 precursors in 2032).
That the number of MHC-binding peptides in HIV-1 remained
constant over time (Fig. 2, middle column) was to be expected,
based on the theory that the MHC polymorphism prevents
pathogens like HIV-1 from escaping MHC binding on a
population level [8,37], and earlier reports that the virulence of
HIV-1 had not changed over time [38,39]. However, other studies
reported that HIV-1 was capable of adapting to common MHC
alleles [40–42], and suggested that HIV-1 was adapting to its new
human host population. Follow-up studies on Moore et al. [40]
showed that their analysis was sensitive to founder effects in the
viral lineage [43] and that without these effects the adaptation of
HIV-1 to the population could only be detected for a small
number of amino acids [44].
In line with our a priori expectations, Yusim et al. [45] proposed
that the clustering of epitopes in HIV-1 proteins was a result of
adaptation of the virus to the monomorphic proteasome and TAP.
However, our results (Fig. 2) refute that expectation: HIV-1 has not
accumulated epitope precursor escapes over the last 30 years. In this
paperweexplorepossiblereasonsforthe apparentlackofadaptation
of HIV-1 to the monomorphic antigen processing machinery.
Selection pressure by CD8
+ T cells
A simple explanation for why we find that HIV-1 is not
accumulating CTL epitope and epitope precursor escapes (Fig. 2)
would be that CD8
+ T cells exert too little selection pressure on
the virus. The role of CD8
+ T cells in controlling a chronic HIV-1
infection has been under debate [46,47], but the strongest
evidence that the virus is under selection pressure of CD8
+ T
cells is that certain immune escape mutations are rapidly reverted
to the wildtype upon entering an HLA-mismatched host [10,48–
50]. Additional evidence comes from CD8
+ T cell depletion
studies of chronic SIV infections in monkeys [51–53], from studies
that show that MHC-heterozygous hosts progress slower to AIDS
than homozygous hosts [54], and from correlates between HIV-1
disease progression and the presence or absence of certain MHC
class I molecules [30,31].
In addition to the strong evidence on the selection pressure
imposed by CD8
+ T cells from the current literature, we studied
the CD8
+ T-cell mediated immune selection pressure on HIV-1 by
testing whether amino acid replacement mutations happen
preferentially in CTL epitopes and their flanking regions. For this
purpose we data-mined the Los Alamos HIV database for
longitudinal within-host HIV-1 sequence data from MHC
genotyped and treatment-naive patients (see Material & Methods,
and Supporting Information). This resulted in 13 patients for
which GAG, NEF and POL protein sequences were available (see
Table S1, S2). We compared for each of these proteins the number
of amino acid replacements that occurred within predicted
epitopes or their flanking regions to the expected number of
mutations. This expected number of mutations is based on the
fraction of the protein that the epitopes and their flanking regions
covered (‘epitope cover’). We found a trend towards mutations
occurring within CTL epitopes or their flanking regions for the
three HIV-1 proteins that were tested (Wilcoxon signed rank test:
p=0.09, with 15 out of 21 samples following the trend).
A surprising observation based on our immune selection
pressure study was that the predicted CTL epitopes within a
single host can cover a large fraction of the viral proteome. For
those samples in the longitudinal within-host data set where
predictors were available for all four of the Human Leukocyte
Figure 3. The predicted fraction of ancestral epitope precursors, MHC-binding peptides and CTL epitopes present in the HIV-1
clade B sequences declines over time. The predicted fraction is plotted per sequence as a dot on the y-axis. Ancestral epitope precursors are
defined by their C-terminal position (Fig. 1, 10th amino acid from the left) in the aligned sequences [3]. Similarly, MHC-binding peptides and CTL
epitopes are defined by their C-terminal, but also by the MHC that they are predicted to bind to. *: significant decrease over time (Kendall Tau rank
correlation test, p,0.01). The consensus sequence [65] is plotted as a square on the right-hand side of each panel.
doi:10.1371/journal.pone.0003525.g003
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cover ranged from 12% to 74%. The average epitope cover of a
single MHC allele for the HIV-1 clade B HXB2 reference
sequence (accession: K03455) was 17%, and all 32 MHC
predictors together covered 94% of the HIV-1 HXB2 virus
proteome.
That we find no significant correlation between the location of
mutations and predicted CTL epitopes might be due to differences
between CTL epitopes in the strength of the immune selection
pressure imposed on them, which would reduce the detection
power of our method of testing for selection pressure. Yewdell et
al. [55] indicated that only half of all CTL epitopes can trigger a
CD8
+ T cell response. The underlying mechanism is poorly
understood, but possibly involves self-tolerance [56,57]. Zafiro-
poulos et al. [58] and Frater et al. [50] showed that the selection
pressure imposed on the virus differs between CTL epitopes. A
possible cause for this variation is whether an epitope is presented
early or late during the infection of a cell [59–61]. Since the trend
we find is confirmed by the current literature, we assert that the
lack of predicted adaptation in HIv-1 (Fig. 2) is not likely to be due
to a lack of immune selection pressure.
Short timespan of population data set
Another possible reason why we find that HIV-1 is not
accumulating CTL epitope and epitope precursor escapes (Fig. 2)
would be that the timespan of our population data set (30 years -
from 1976 to 2006) is too short to detect an evolutionary process
like the adaptation of a virus to its host. To test this, we predicted
the epitope precursors of the putative HIV-1 clade B ancestor
sequence [35] and plotted the fraction of ancestral epitope
precursors contained in each sequence of our population data
set against the sampling date (Fig. 3). In this way the
‘immunological similarity’ of a sequence with the ancestor
sequence can be visualized. This similarity is expected to decline
over time, based on the destruction of ancestral epitope precursors
by neutral amino acid substitutions [62–64], and by the
accumulation of escapes from CD8
+ T cell responses within hosts.
If the time covered by our population data set is sufficient, we
should see a decrease over time in the immunological similarity of
current-day sequences to the ancestral HIV-1 sequence.
Indeed, for ancestral epitope precursors as well as for ancestral
MHC-binding peptides and CTL epitopes, we found that the
density declined significantly over time in the six largest proteins of
HIV-1 (Kendall Tau rank correlation test, p,0.01 in 17/18 tests).
The only exception was a non-significant decrease in the number
of predicted ancestral epitopes in HIV-1 NEF (Fig. 3, bottom right
panel). Analysis of the NEF protein subset of the population data
set revealed that in the Kroatian population the number of
ancestral epitopes in NEF was increasing over time. Whether this
increase reflects a particular adaptation of the virus, or is due to a
founder effect in the Kroatian subpopulation that was over-
sampled in the HIV Sequence Compendium data set is not
known. The three smallest proteins of HIV-1 (TAT, VPR and
VPU) yielded no significant results, which indicates that at protein
sizes of less than 100 amino acids our method becomes insensitive.
The HIV-1 clade B consensus sequence (Fig. 3, open square on
the right-hand side of each panel) is more similar to the predicted
ancestral sequence than most of the HIV-1 sample sequences
themselves are, which indicates that HIV-1 is undergoing
divergent evolution. This is inconsistent with the idea that HIV-
1 is undergoing a large-scale global adaptation to the human host
(which would imply a convergent evolution process). Based on the
results presented thus far, we conclude that the evolution of HIV-1
seems largely determined by the loss of ancestral epitopes due to
antigenic drift, by local adaptation of the virus to each individual
host, and by the reversion of earlier adaptations.
Finally, the rate at which ancestral epitopes and epitope
precursors disappear (Fig. 3, grey lines) gives a novel way to
estimate in what year HIV-1 clade B was introduced into the
human population. The age of the ancestral HIV-1 B sequence
can be predicted by extrapolating the regression line back to where
the fraction of ancestral epitopes or epitope precursors in HIV-1
sequences becomes one, assuming that the loss over time has been
linear. Each protein and each category (precursor, MHC binding,
epitopes) generates a separate prediction for the age of the
ancestral sequence. For the larger genes ENV, GAG and POL, the
estimated ancestral age is 1939613, whereas for the smaller genes
it is 1900654 years. The estimate for the larger genes concurs with
the findings of Korber et al. [35], who dated the ancestral
sequence on 1920–1940.
Summarizing: the analysis of the loss of ancestral epitope
precursors shows that 30 years is long enough to pick up
evolutionary processes in the larger proteins of HIV-1 (.100
amino acids). Therefore, the lack of adaptation to epitope
precursors in HIv-1 (Fig. 2) should not be attributed to the
relatively short time span of the population data set.
Rarity of precursor escapes
Brander et al. [66] hypothesized that the proteasome and TAP
should be rather non-specific for their substrate in order to fulfil their
intracellular functions. Therefore, most mutations should not affect
antigen processing, and as a result epitope precursor escapes would
be harder to generate than MHC binding escapes. Although several
studies have clearly shown that antigen processing escapes do exist
[64,66], the frequency of successful antigen processing escapes in
vivo could be so low that these kind of escapes play no role in the
evolution of HIV-1, which would explain why HIV-1 is not
accumulating epitope precursor escapes (Fig. 2).
We used the MHC-pathway model to determine the frequency
of antigen processing escapes in a longitudinal within-host HIV-1
sequence data set (27 HIV-1 proteins from a total of 13 different
patients, see Material & Methods, Table S1 and S2). We found
that 38 out of a total of 375 predicted CTL epitopes were escaped
by the virus (10.1%) during the time spanned by the longitudinal
within-host data set. Of these 38 escaped CTL epitopes, 34 (89%)
contained one or more mutations that prevented the peptide from
binding to its associated MHC molecule, and 6 (16%) contained
one or more mutations in the epitope or the epitope’s flanking
region that prevented antigen processing of the epitope precursor.
A second way to study the frequency of epitope precursor
escapes is to study the predicted effect of a single amino acid
substitution on the number of CTL epitopes in a HIV-1 protein.
While this approach completely ignores functional constraints on
proteins, it has the advantage that we can calculate the average
effect of a single mutation on the escape of CTL epitopes. This
procedure was repeated a large number of times, until on average
each amino acid in the HXB2 reference sequence had been
mutated five times (previous mutations were reversed before a new
one was generated). In 3.8% of the cases this procedure resulted in
the loss of one or more epitopes per MHC allele. In 38% of these
escape mutations the epitope precursor was no longer processed
correctly by the proteasome or TAP (Table 1).
The amino acid substitution simulations on the HIV-1 HXB2
reference sequence showed that new CTL epitopes are predicted
to be readily created by random mutations (Table 1). Similarly,
comparing the early and late timepoints of the longitudinal within-
host data set showed that 56 new CTL epitopes were predicted to
have arisen. Although the generation of new CTL epitopes during
Adaptation of HIV
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to occur in reality [67,68]. There are several reasons why new
CTL epitopes could come about, despite immune selection
pressure: 1) a single mutation could escape an epitope against
which a strong immune response was directed, while at the same
time create a new epitope with a weaker response [67], 2) if a small
number of strong immune responses determine most of the fitness
of the virus, adding a single weak response to the existing weak
responses has a negligible effect on the fitness of the virus, 3) the
new epitopes might not be recognized by any of the CD8
+ T cell
receptors of the host [55], and 4) the time between the generation
of a new epitope and the expansion of a CD8
+ T cell response
against this new epitope provides a time window during which new
CTL epitopes in a HIV-1 sequence are not penalized [69].
The analysis of the longitudinal within-host data set and the
simulated HIV-1 HXB2 reference sequence mutations established
that antigen processing escapes occur relatively frequently, and
thus that the predicted lack of antigen processing adaptation of
HIV-1 (Fig. 2) is not because precursor escapes are too hard to
generate. The analysis also showed that new CTL epitopes are
frequently generated during the within-host evolution of the virus.
Polymorphism and Specificity
In the previous sections we investigated three possible
explanations for the predicted lack of adaptation of HIV-1 to
the monomorphic antigen processing pathway (Fig. 2), but found
no compelling evidence for any of them. Here we propose an
alternative explanation: as each MHC class I allele utilizes only a
small fraction of the available HIV-1 epitope precursors, not all of
the epitope precursors in a host are under selection pressure.
When a virus is transmitted from one host to a new host with a
different set of MHC molecules a large number of the epitope
precursors that were previously under immune selection pressure
are no longer so. Escape mutations in those epitope precursors can
subsequently revert to the wildtype sequence. A visual example of
this mechanism is depicted in Fig. 4, in which a HIV-1 protein is
passed from one fictitious host to another.
While the proposed mechanism is straightforward and plausible,
its protective effect depends on the fraction of epitope precursors
that is under selection pressure in the donor host, but no longer in
the recipient host. This is directly influenced by the specificity and
promiscuity of the MHC alleles of both host and donor: the more
specific the MHC binding is, the smaller the subset of epitope
precursors is that is used by the MHCs of the host, and therefore
the larger the typical fraction of epitope precursors is that is
released from selection pressure when the virus changes from one
host to the other. We estimated this fraction with a simple model
in which we create fictitious hosts with random sets of MHC
alleles, and transmit the HIV-1 HXB2 reference sequence from
one host to another. Each time the virus is transmitted, we
calculate the fraction of the epitope precursors that were used by
the MHC alleles of the donor host, but are not utilized in the
recipient host. In this way we estimated that on average 18% of
the epitope precursors are under selection pressure in a host, i.e.
are an actual epitope in that host. 66% of these actual epitopes will
be released from selection pressure in the next host (Fig. 5).
Alternatively, the protective effect can also be calculated at the
level of amino acid positions rather than at the level of epitope
precursors. By doing so we predicted that on average 49% of the
amino acid positions are under selection pressure in a random
host, and that 39% of this group of 49% is released from selection
pressure upon transfer of the virus to a new host. These two
estimates represent the extreme ends of how much escape
mutations in one epitope precursor influence the processing and
presentation of another epitope precursor. The true fraction of
epitope precursors that is released from selection pressure when a
virus travels from one host to the next should lie somewhere in
between this range of 39%–66%. Note that the range depends on
the thresholds we used for proteasome, TAP and MHC binding.
Increasing the specificity of the MHC binding from an IC50 of
500 nM to 50 nM increases the fraction of released epitopes to a
range of 76%–83%, and lowers the average number of predicted
CTL epitopes from 145 to 18 epitopes per host per viral sequence.
Decreasing the specificity of the MHC binding to 5000 nM
decreases the fraction of released CTL epitopes to a range of 6%–
31%, but with this threshold we predict an unrealistically large
number of CTL epitopes (514) per viral sequence.
Based on these predictions, we argue that the magnitude of this
MHC specificity and polymorphism-dependent release mechanism
is large enough to play an essential role in slowing down the
adaptation of HIV-1 to the proteasome and TAP. Its exact effect on
the evolution of HIV-1 will also depend on other characteristics of
the virus, such as the transmission rate of the virus, and the balance
betweentherateof escapemutationsand therate ofescape reversion
Table 1. Effect of random amino acid substitutions on the
average loss and gain of CTL epitopes per MHC allele in the
HIV-1 HXB2 reference sequence.
loss of
epitopes
gain of
epitopes
Mutations affecting epitope count 3.8% 4.3%
due to processing escapes 38% 40%
due to MHC-binding escapes 80% 81%
doi:10.1371/journal.pone.0003525.t001
Figure 4. The effect of MHC specificity and polymorphism on the selection pressure on epitope precursors. This example shows the
first 100 amino acids of the NEF protein of the HIV-1 HXB2 reference sequence (accession: K03455), and the precursors and epitopes for two fictitious
hosts. The lines represent the epitope precursors generated by the monomorphic proteasome and TAP. The black lines depict those epitope
precursors that are used by the MHC alleles. In this example, 4 out of 5 epitope precursors were released from selection pressure, as were 32 out of 70
amino acids.
doi:10.1371/journal.pone.0003525.g004
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factors will determine the eventual degree of adaptation to the
antigen presentation pathway that viruses like HIV-1 can reach.
Discussion
The total number of predicted epitope precursors and CTL
epitopes in a large population data set of HIV-1 clade B sequences
is not decreasing over time (Fig. 2). This is in contrast to our initial
expectation that HIV-1 would be able to adapt to the
monomorphic steps of the antigen presentation pathway (i.e. the
proteasome and TAP) to evade the presentation of CTL epitopes
derived from its proteins on the cell surface. We investigated three
possible factors that could explain why we did not detect
adaptation: 1) possible lack of CD8
+ T cell selection pressure, 2)
the evolutionary short timespan of 30 years of our population data
set (Fig. 3), and 3) the possible rarity of epitope precursor escapes
(Table 1), but found no compelling evidence for any of them.
In the last section of the results we added and discussed a fourth
possibility, namely that the adaptation of HIV-1 to epitope
precursors is limited by frequent loss of the immune selection
pressure on epitope precursor escapes as the virus passes from one
host to another (Fig. 4). We proceeded by quantifying that a
typical proteasome or TAP escape mutation is released from
selection in 39% to 66% of the human hosts. We propose that this
loss of selection pressure on epitope precursors is one of the main
factors that determine the eventual degree of adaptation to epitope
precursors that HIV-1 can reach on the population level (Fig. 5).
Other factors are the transmission rate, the rate at which epitope
precursor escapes are acquired, and the rate at which they are lost
or reverted [42].
Based on our understanding of this mechanism, we speculate
that only one of the steps in the antigen presentation pathway has
to be polymorphic to prevent pathogens from adapting to any step
in the pathway. The mechanism functions best when the
polymorphy occurs at the most specific step in the pathway, as
that increases the fraction of epitope precursors that is not under
selection pressure. While in humans it is the MHC class I
molecules that are highly polymorphic and specific, other solutions
do appear to exist. The TAP molecules of rats are more specific
than the human TAP, and have a limited functional polymor-
phism [70], and the TAP and MHC genes of chickens are equally
polymorphic on the nucleotide level [71]. We are currently
exploring the conditions that determine which of the steps of the
antigen presentation pathway become polymorphic using an
agent-based host-pathogen model.
The lack of any large-scale adaptation of HIV-1 to reduce its
number of CTL epitopes -as reported by this study-is not necessarily
in contradiction with the possible fixation of certain CTL epitope
escape mutations at the population level [41,44], especially if these
occur in combination with compensatory mutations [72]. However,
our analysis indicates that the fixation of CTL epitope escape
mutationsare not occurring at a scale that makes itdetectableamidst
the constant destruction and generation of CTL epitopes due to
neutral amino acid substitutions (Fig. 3, Table 1). Furthermore, we
have only studied the adaptation of HIV-1 to escape antigen
presentation by means of amino acid substitutions. HIV-1 also
influences epitope presentation by blocking TAP transport [73] and
downregulating MHC molecules [74]. Adaptation to the pathway
could be occurring at this level, rather than at the level of individual
CTL epitopes. However, current findings that individual escape
mutations can have a large impact on viral load during within-host
Figure 5. The number of epitope precursors that bind to MHC alleles in the donor host but no longer in the recipient host is
calculated based on a 1000 simulated passages of the HIV-1 HXB2 reference sequence (accession: K03455) between two hosts. The
hosts are randomly created from a set of 18 different HLA-A molecules and 14 different HLA-B molecules. On average, the 4 MHC alleles of a host bind
18% (145) of the 818 predicted epitope precursors. Of these 145 epitope precursors, an average of 34% can bind to one of the MHC alleles of a
recipient host, whereas 66% is no longer under selection pressure. 95% confidence intervals (c.i) are shown in the figure. The overlap in epitope
precursors used by the donor and recipient is partially due to overlapping MHC molecules (in 42% of the cases the randomly created donor and
recipient shared by chance one or more MHC alleles), and partially due to the promiscuity of MHC alleles.
doi:10.1371/journal.pone.0003525.g005
Adaptation of HIV
PLoS ONE | www.plosone.org 7 October 2008 | Volume 3 | Issue 10 | e3525evolution [68,75], suggests that there is still a strong selection
pressure on individual CTL epitopes.
In summary: the monomorphic parts of the antigen presentation
pathway are protected from viral immune escape adaptations
because only a subset of the epitope precursors can be presented by
the MHC alleles of a particular host. Because of the MHC
polymorphism, this subset differs between hosts. As a result, epitope
precursor escape mutations are frequently released from immune
selection pressure when pathogens spread through a population, and
can revert to the wildtype sequence. The protective effect of this
mechanismincreaseswiththepolymorphismoftheMHCclassIand
the specificity of individual MHC class I alleles.
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